{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T23:55:42Z","timestamp":1780530942121,"version":"3.54.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-024-11341-0","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T14:57:08Z","timestamp":1722956228000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A retrospective analysis of e-prescriptions for non-communicable diseases on a telehealth platform in Malaysia"],"prefix":"10.1186","volume":"24","author":[{"given":"Hui Yin","family":"Yow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason Siau Ee","family":"Loo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Hang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui Che","family":"Oui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megat Helmi","family":"Megat Mohd Zubairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nusaibah","family":"Abdul Rahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"key":"11341_CR1","unstructured":"World Health Organization. Noncommunicable diseases. 2023. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/noncommunicable-diseases. Accessed 30 Sept 2023."},{"issue":"10258","key":"11341_CR2","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/s0140-6736(20)30925-9","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","unstructured":"GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of Disease Study 2019. Lancet. 2020;396(10258):1204\u201322. https:\/\/doi.org\/10.1016\/s0140-6736(20)30925-9. Epub 2020\/10\/19.","journal-title":"Lancet"},{"issue":"10152","key":"11341_CR3","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/s0140-6736(18)31992-5","volume":"392","author":"NCDC2030 collaborators","year":"2018","unstructured":"collaborators NCDC2030. NCD countdown 2030: worldwide trends in non-communicable disease mortality and progress towards sustainable development goal target 3.4. Lancet. 2018;392(10152):1072\u201388. https:\/\/doi.org\/10.1016\/s0140-6736(18)31992-5","journal-title":"Lancet"},{"issue":"1","key":"11341_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.2478\/s13382-014-0326-0","volume":"28","author":"W-Y Low","year":"2015","unstructured":"Low W-Y, Lee Y-K, Samy AL. Non-communicable diseases in the Asia-Pacific region: prevalence, risk factors and community-based prevention. Int J Occup Med Environ Health. 2015;28(1):20\u20136. https:\/\/doi.org\/10.2478\/s13382-014-0326-0","journal-title":"Int J Occup Med Environ Health"},{"key":"11341_CR5","doi-asserted-by":"publisher","unstructured":"Chandran A, Selva Kumar S, Hairi NN, Low WY, Mustapha FI. Non-communicable disease surveillance in Malaysia: an overview of existing systems and priorities going forward. Front Public Health. 2021;9. https:\/\/doi.org\/10.3389\/fpubh.2021.698741","DOI":"10.3389\/fpubh.2021.698741"},{"key":"11341_CR6","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2147\/RMHP.S256165","volume":"13","author":"NT Castillo-Carandang","year":"2020","unstructured":"Castillo-Carandang NT, Buenaventura RD, Chia Y-C, Do Van D, Lee C, Duong NL, et al. Moving towards optimized noncommunicable disease management in the ASEAN region: recommendations from a review and multidisciplinary expert panel. Risk Manag Healthc Policy. 2020;13:803\u201319. https:\/\/doi.org\/10.2147\/RMHP.S256165","journal-title":"Risk Manag Healthc Policy"},{"issue":"1","key":"11341_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12875-019-1019-3","volume":"20","author":"CI Fernandez-Lazaro","year":"2019","unstructured":"Fernandez-Lazaro CI, Garc\u00eda-Gonz\u00e1lez JM, Adams DP, Fernandez-Lazaro D, Mielgo-Ayuso J, Caballero-Garcia A, et al. Adherence to treatment and related factors among patients with chronic conditions in primary care: a cross-sectional study. BMC Fam Pract. 2019;20(1):132. https:\/\/doi.org\/10.1186\/s12875-019-1019-3","journal-title":"BMC Fam Pract"},{"key":"11341_CR8","doi-asserted-by":"publisher","unstructured":"Budreviciute A, Damiati S, Sabir DK, Onder K, Schuller-Goetzburg P, Plakys G, et al. Management and prevention strategies for non-communicable diseases (NCDs) and their risk factors. Front Public Health. 2020;8. https:\/\/doi.org\/10.3389\/fpubh.2020.574111","DOI":"10.3389\/fpubh.2020.574111"},{"issue":"3","key":"11341_CR9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0168-8510(00)00138-X","volume":"56","author":"M Perleth","year":"2001","unstructured":"Perleth M, Jakubowski E, Busse R. What is \u2018best practice\u2019 in health care? State of the art and perspectives in improving the effectiveness and efficiency of the European health care systems. Health Policy. 2001;56(3):235\u201350. https:\/\/doi.org\/10.1016\/S0168-8510(00)00138-X","journal-title":"Health Policy"},{"issue":"15","key":"11341_CR10","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1001\/jama.291.15.1850","volume":"291","author":"MA Fischer","year":"2004","unstructured":"Fischer MA, Avorn J. Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA. 2004;291(15):1850\u20136. https:\/\/doi.org\/10.1001\/jama.291.15.1850","journal-title":"JAMA"},{"issue":"3","key":"11341_CR11","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1093\/intqhc\/mzv024","volume":"27","author":"Y-T Yang","year":"2015","unstructured":"Yang Y-T, Iqbal U, Ko H-L, Wu C-R, Chiu H-T, Lin Y-C, et al. The relationship between accessibility of healthcare facilities and medical care utilization among the middle-aged and elderly population in Taiwan. Int J Qual Health Care. 2015;27(3):222\u201331. https:\/\/doi.org\/10.1093\/intqhc\/mzv024","journal-title":"Int J Qual Health Care"},{"issue":"3","key":"11341_CR12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1503\/cmaj.111270","volume":"184","author":"RL Michael","year":"2012","unstructured":"Michael RL, Lucy C, Irfan AD, Deborah H, Steven GM. The effect of cost on adherence to prescription medications in Canada. Can Med Assoc J. 2012;184(3):297. https:\/\/doi.org\/10.1503\/cmaj.111270","journal-title":"Can Med Assoc J"},{"issue":"4","key":"11341_CR13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1377\/hlthaff.22.4.220","volume":"22","author":"R Mojtabai","year":"2003","unstructured":"Mojtabai R, Olfson M. Medication costs, adherence, and health outcomes among medicare beneficiaries. Health Aff. 2003;22(4):220\u20139. https:\/\/doi.org\/10.1377\/hlthaff.22.4.220","journal-title":"Health Aff"},{"issue":"16","key":"11341_CR14","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1056\/NEJMsr1503323","volume":"377","author":"RV Tuckson","year":"2017","unstructured":"Tuckson RV, Edmunds M, Hodgkins ML, Telehealth. NEJM. 2017;377(16):1585\u201392. https:\/\/doi.org\/10.1056\/NEJMsr1503323","journal-title":"NEJM"},{"issue":"Suppl 1","key":"11341_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1258\/1357633021937604","volume":"8","author":"D Hailey","year":"2002","unstructured":"Hailey D, Roine R, Ohinmaa A. Systematic review of evidence for the benefits of telemedicine. J Telemed Telecare. 2002;8(Suppl 1):1\u20137. https:\/\/doi.org\/10.1258\/1357633021937604","journal-title":"J Telemed Telecare"},{"key":"11341_CR16","unstructured":"Potter AJMA, Ward MMP, Natafgi NMPH, Ullrich F, MacKinney ACMDMS, Bell ALMHA et al. Perceptions of the benefits of telemedicine in rural communities. Perspect Health Inf Manag. 2016:1\u201313."},{"issue":"1","key":"11341_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6947-12-1","volume":"12","author":"P Zanaboni","year":"2012","unstructured":"Zanaboni P, Wootton R. Adoption of telemedicine: from pilot stage to routine delivery. BMC Med Inf Decis Mak. 2012;12(1):1. https:\/\/doi.org\/10.1186\/1472-6947-12-1","journal-title":"BMC Med Inf Decis Mak"},{"issue":"8","key":"11341_CR18","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/01.Asw.0000669916.01793.93","volume":"33","author":"EC Mills","year":"2020","unstructured":"Mills EC, Savage E, Lieder J, Chiu ES. Telemedicine and the COVID-19 pandemic: are we ready to go live? Adv Skin Wound Care. 2020;33(8):410\u20137. https:\/\/doi.org\/10.1097\/01.Asw.0000669916.01793.93","journal-title":"Adv Skin Wound Care"},{"issue":"4","key":"11341_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/1357633X20960638","volume":"28","author":"EE Thomas","year":"2020","unstructured":"Thomas EE, Haydon HM, Mehrotra A, Caffery LJ, Snoswell CL, Banbury A, et al. Building on the momentum: sustaining telehealth beyond COVID-19. J Telemed Telecare. 2020;28(4):301\u20138. https:\/\/doi.org\/10.1177\/1357633X20960638","journal-title":"J Telemed Telecare"},{"key":"11341_CR20","doi-asserted-by":"publisher","unstructured":"Loo JS, Yow HY, Ten YY, Govindaraju K, Megat Mohd Zubairi MH, Oui HC, et al. Exploring the rise of telehealth services in Malaysia: a retrospective study. Digit Health. 2023;9. https:\/\/doi.org\/10.1177\/20552076231216275","DOI":"10.1177\/20552076231216275"},{"key":"11341_CR21","unstructured":"Malaysia Digital Economy Blueprint. In: economic planning unit Prime Minister\u2019s department, editor. Putrajaya, Malaysia: Economic Planning Unit, Prime Minister\u2019s Department. 2021. https:\/\/www.ekonomi.gov.my\/sites\/default\/files\/2021-02\/malaysia-digital-economy-blueprint.pdf. Accessed 3 May 2024."},{"key":"11341_CR22","unstructured":"Act A. Poison (Amendment) Act 2022. 2022."},{"issue":"43","key":"11341_CR23","doi-asserted-by":"publisher","first-page":"e8257","DOI":"10.1097\/md.0000000000008257","volume":"96","author":"WM Chu","year":"2017","unstructured":"Chu WM, Ho HE, Huang KH, Tsan YT, Liou YS, Wang YH, et al. The prescribing trend of oral antidiabetic agents for type 2 diabetes in Taiwan: an 8-year population-based study. Medicine. 2017;96(43):e8257. https:\/\/doi.org\/10.1097\/md.0000000000008257","journal-title":"Medicine"},{"issue":"6","key":"11341_CR24","doi-asserted-by":"publisher","first-page":"e057510","DOI":"10.1136\/bmjopen-2021-057510","volume":"12","author":"R Julie","year":"2022","unstructured":"Julie R, Emily GM, Tibor S, James MB, Laurent A. Treatment and prescribing trends of antihypertensive drugs in 2.7 million UK primary care patients over 31 years: a population-based cohort study. BMJ Open. 2022;12(6):e057510. https:\/\/doi.org\/10.1136\/bmjopen-2021-057510","journal-title":"BMJ Open"},{"key":"11341_CR25","doi-asserted-by":"publisher","unstructured":"Katzmann JL, Kieble M, Enners S, B\u00f6hm M, Mahfoud F, Laufs U, et al. Trends in ezetimibe prescriptions as monotherapy or fixed-dose combination in Germany 2012\u20132021. Front Cardiovasc Med. 2022;9. https:\/\/doi.org\/10.3389\/fcvm.2022.912785","DOI":"10.3389\/fcvm.2022.912785"},{"key":"11341_CR26","unstructured":"Sivasampu S, Lim Y, Rahman A, Hwong W, Goh P, Abdullah N. National medical care statistics: primary care. 2012. https:\/\/www.crc.gov.my\/wp-content\/uploads\/documents\/report\/NMCS_PRIMARY_CARE_2012_FullReport.pdf. Accessed 3 May 2024."},{"issue":"1","key":"11341_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/ijpp\/riab075","volume":"30","author":"WS Su","year":"2021","unstructured":"Su WS, Thum CM, Loo JSE. An exploratory analysis of general practitioner prescribing patterns in Malaysia using a health insurance claims database. Int J Pharm Pract. 2021;30(1):59\u201366. https:\/\/doi.org\/10.1093\/ijpp\/riab075","journal-title":"Int J Pharm Pract"},{"key":"11341_CR28","doi-asserted-by":"crossref","unstructured":"McKinney W. Data structures for statistical computing in python. Proc Python Sci Conf. 2010:445.","DOI":"10.25080\/Majora-92bf1922-00a"},{"issue":"3","key":"11341_CR29","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1109\/MCSE.2007.55","volume":"9","author":"JD Hunter","year":"2007","unstructured":"Hunter JD, Matplotlib. A 2D graphics environment. Comput Sci Eng. 2007;9(3):90\u20135. https:\/\/doi.org\/10.1109\/MCSE.2007.55","journal-title":"Comput Sci Eng"},{"key":"11341_CR30","unstructured":"ICD-10 version. 2019. 2019. https:\/\/icd.who.int\/browse10\/2019\/en#\/. Accessed 31 January 2023."},{"key":"11341_CR31","unstructured":"Index ATCDDD. 2023. 2023. https:\/\/www.whocc.no\/atc_ddd_index\/. Accessed 31 January 2023."},{"key":"11341_CR32","unstructured":"Malaysian Society of Hypertension, Ministry of Health Malaysia, Academy of Medicine of Malaysia. Clinical practice guidelines: management of hypertension 5th ed. 2018. https:\/\/www.moh.gov.my\/moh\/resources\/penerbitan\/CPG\/MSH Hypertension CPG 2018 V3.8 FA.pdf. Accessed 31 January 2023."},{"key":"11341_CR33","unstructured":"Ministry of Health Malaysia. Clinical practice guidelines: management of type 2 diabetes mellitus. 6th ed. 2020. https:\/\/www.moh.gov.my\/moh\/resources\/Penerbitan\/CPG\/Endocrine\/CPG_T2DM_6th_Edition_2020_13042021.pdf. Accessed 31 January 2023."},{"key":"11341_CR34","unstructured":"Institute for Public Health, National Institutes of Health, Ministry of Health Malaysia. National Health and Morbidity Survey (NHMS). 2019: Vol. I: NCDs \u2013 Non-Communicable Diseases: Risk Factors and other Health Problems. Malaysia: 2020. https:\/\/iku.moh.gov.my\/images\/IKU\/Document\/REPORT\/NHMS2019\/Report_NHMS2019-NCD_v2.pdf. Accessed 31 January 2023."},{"issue":"7","key":"11341_CR35","doi-asserted-by":"publisher","first-page":"e8146","DOI":"10.2196\/mhealth.8146","volume":"6","author":"S Saleh","year":"2018","unstructured":"Saleh S, Farah A, Dimassi H, El Arnaout N, Constantin J, Osman M, et al. Using mobile health to enhance outcomes of noncommunicable diseases care in rural settings and refugee camps: randomized controlled trial. JMIR MHealth Uhealth. 2018;6(7):e8146.","journal-title":"JMIR MHealth Uhealth"},{"issue":"1","key":"11341_CR36","doi-asserted-by":"publisher","first-page":"4","DOI":"10.17116\/terarkh20158714-9","volume":"87","author":"SA Bo\u012dtsov","year":"2015","unstructured":"Bo\u012dtsov SA, Vylegzhanin SV. Prevention of noncommunicable diseases in a local therapist\u2019s practice: content, problems, solution ways, and prospects. Ter Arkh. 2015;87(1):4\u20139.","journal-title":"Ter Arkh"},{"issue":"3","key":"11341_CR37","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1365-2125.2010.03681.x","volume":"70","author":"A Johnston","year":"2010","unstructured":"Johnston A, Stafylas P. Stergiou GSJBjocp. Effectiveness, safety and cost of drug substitution in hypertension. Br J Clin Pharmacol. 2010;70(3):320\u201334.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"11341_CR38","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1161\/hypertensionaha.120.16667","volume":"78","author":"R Chen","year":"2021","unstructured":"Chen R, Suchard MA, Krumholz HM, Schuemie MJ, Shea S, Duke J, et al. Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study. Hypertension. 2021;78(3):591\u2013603. https:\/\/doi.org\/10.1161\/hypertensionaha.120.16667","journal-title":"Hypertension"},{"issue":"6","key":"11341_CR39","doi-asserted-by":"publisher","first-page":"e1001244","DOI":"10.1371\/journal.pmed.1001244","volume":"9","author":"S Basu","year":"2012","unstructured":"Basu S, Andrews J, Kishore S, Panjabi R, Stuckler D. Comparative performance of private and public healthcare systems in low- and middle-income countries: a systematic review. PLoS Med. 2012;9(6):e1001244. https:\/\/doi.org\/10.1371\/journal.pmed.1001244","journal-title":"PLoS Med"},{"issue":"4","key":"11341_CR40","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1681\/asn.2008070667","volume":"20","author":"BE de Galan","year":"2009","unstructured":"de Galan BE, Perkovic V, Ninomiya T, Pillai A, Patel A, Cass A, et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol. 2009;20(4):883\u201392. https:\/\/doi.org\/10.1681\/asn.2008070667","journal-title":"J Am Soc Nephrol"},{"key":"11341_CR41","doi-asserted-by":"crossref","unstructured":"Strauss MH, Hall AS, Narkiewicz K. The combination of beta-blockers and ACE inhibitors across the spectrum of cardiovascular diseases. Cardiovasc Drug Ther. 2021:1\u201314.","DOI":"10.1007\/s10557-021-07248-1"},{"issue":"4","key":"11341_CR42","doi-asserted-by":"publisher","first-page":"482","DOI":"10.5603\/EP.2017.0050","volume":"68","author":"MP Wr\u00f3bel","year":"2017","unstructured":"Wr\u00f3bel MP, Marek B, Kajdaniuk D, Rokicka D, Szymborska-Kajanek A, Strojek K. Metformin\u2014a new old drug. Endokrynologia Polska. 2017;68(4):482\u201396.","journal-title":"Endokrynologia Polska"},{"issue":"8","key":"11341_CR43","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/14740338.2019.1626823","volume":"18","author":"EM Lamos","year":"2019","unstructured":"Lamos EM, Hedrington M, Davis SN. An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors. Expert Opin Drug Saf. 2019;18(8):691\u2013701. https:\/\/doi.org\/10.1080\/14740338.2019.1626823","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"11341_CR44","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","volume":"143","author":"M Packer","year":"2021","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial. Circ. 2021;143(4):326\u201336.","journal-title":"Circ"},{"issue":"11","key":"11341_CR45","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/ejhf.1548","volume":"21","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, DeMets DL, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Langkilde AM, et al. The dapagliflozin and prevention of adverse-outcomes in heart failure (DAPA\u2010HF) trial: baseline characteristics. Eur J Heart Fail. 2019;21(11):1402\u201311.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"11341_CR46","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1093\/ndt\/gfz290","volume":"35","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Chertow GM, Correa-Rotter R, Greene T, Hou F-F, et al. Rationale and protocol of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transpl. 2020;35(2):274\u201382.","journal-title":"Nephrol Dial Transpl"},{"key":"11341_CR47","doi-asserted-by":"crossref","unstructured":"Liew A, Lydia A, Matawaran BJ, Susantitaphong P, Tran HTB, Lim LL. Practical considerations for the use of SGLT-2 inhibitors in the Asia-Pacific countries-an expert consensus statement. Nephrol. 2023.","DOI":"10.1111\/nep.14167"},{"key":"11341_CR48","unstructured":"Food and Drug Administration. FDA drug safety communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury 2011. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-new-restrictions-contraindications-and-dose-limitations-zocor. Accessed 11 Sept 2023."},{"issue":"10186","key":"11341_CR49","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1016\/S0140-6736(19)30541-0","volume":"393","author":"I Raber","year":"2019","unstructured":"Raber I, McCarthy CP, Vaduganathan M, Bhatt DL, Wood DA, Cleland JG, et al. The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet. 2019;393(10186):2155\u201367.","journal-title":"Lancet"},{"key":"11341_CR50","unstructured":"Ministry of Health Malaysia. Malaysian statistics on medicines. Pharmaceutical Services Programme. editor.: Pharmaceutical Services Programme; 2020."},{"key":"11341_CR51","doi-asserted-by":"crossref","unstructured":"Paciaroni M, Ince B, Hu B, Jeng J-S, Kutluk K, Liu L et al. Benefits and risks of clopidogrel vs. aspirin monotherapy after recent ischemic stroke: a systematic review and meta-analysis. Cardiovasc Ther. 2019;1607181.","DOI":"10.1155\/2019\/1607181"},{"issue":"24","key":"11341_CR52","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJM200006153422402","volume":"342","author":"CL Bennett","year":"2000","unstructured":"Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. NEJM. 2000;342(24):1773\u20137. https:\/\/doi.org\/10.1056\/NEJM200006153422402","journal-title":"NEJM"},{"issue":"1","key":"11341_CR53","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1164\/rccm.202109-2205PP","volume":"205","author":"HK Reddel","year":"2022","unstructured":"Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, et al. Global initiative for asthma strategy 2021: executive summary and rationale for key changes. Am J Respir Crit Care Med. 2022;205(1):17\u201335.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"11341_CR54","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41533-023-00330-1","volume":"33","author":"ML Levy","year":"2023","unstructured":"Levy ML, Bacharier LB, Bateman E, Boulet L-P, Brightling C, Buhl R, et al. Key recommendations for primary care from the 2022 global initiative for asthma (GINA) update. NPJ Prim Care Respir Med. 2023;33(1):7.","journal-title":"NPJ Prim Care Respir Med"},{"issue":"6","key":"11341_CR55","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1164\/rccm.200210-1142PP","volume":"167","author":"PJ Barnes","year":"2003","unstructured":"Barnes PJ. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med. 2003;167(6):813\u20138.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-024-11341-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-024-11341-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-024-11341-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T14:58:42Z","timestamp":1722956322000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-024-11341-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["11341"],"URL":"https:\/\/doi.org\/10.1186\/s12913-024-11341-0","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,6]]},"assertion":[{"value":"24 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from the Universiti Malaya Research Ethics Committee (UM.TNC2\/UMREC_2038, 28th July 2022). Consent was not required in this study given the retrospective nature of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This is not applicable as the data was provided in an anonymized format. The data were reported collectively without reference to an individual.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"897"}}